Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Arsenic Trioxide × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 7 Plasma cell 2 Gynecologic 2 Gastrointestinal 2 Thoracic 1 Sarcoma 1 Other solid neoplasm 1 Myeloid 1 Genitourinary 1 Dermatologic 1 CNS 1

Conditions

Skin Neoplasms 1 Carcinoma, Basal Cell 1

Interventions

Ipilimumab 82 pembrolizumab 79 Nivolumab 73 Cyclophosphamide 62 fludarabine phosphate 51 aldesleukin 47 Interleukin-2 34 Dacarbazine 31 fludarabine 29 Vemurafenib 29 trametinib 26 dabrafenib 25 Temozolomide 23 Aminolevulinic Acid 19 Whole-Body Irradiation 18 Radiosurgery 17 Bevacizumab 17 Peripheral Blood Stem Cell Transplantation 16 Carboplatin 16 3-ingenyl angelate 16 Radiotherapy 15 Mycophenolic Acid 15 HhAntag691 14 Tacrolimus 13 Paclitaxel 13 Introns 13 Interferon alpha-2 13 Cyclosporine 13 CTLA-4 Antigen 13 Antilymphocyte Serum 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01791894 2018-06-08

ATO

Stanford University

Phase 1/2 Completed

5 enrolled 9 charts

Carcinoma, Basal Cell, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡